Physician profile
Julia M Schwartz
NPI 1134168685
$2,963.80
in general payments reported to CMS, 2019-2025
22 companies · $89.79 in 2025
The $89.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $342 · 2021: $597 · 2022: $913 · 2023: $14.85 · 2024: $83.80 · 2025: $89.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.49 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $411.57 | 2019-2024 | Veozah |
| Amgen INC. | $366.89 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $365.35 | 2019-2022 | |
| Lilly USA, LLC | $289.82 | 2019-2022 | |
| Novo Nordisk INC | $253.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $197.55 | 2019-2022 | |
| Abbvie INC. | $178.67 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $146.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.01 | 2019-2024 | Eohilia |
| Biohaven Pharmaceutical Holding Company LTD. | $79.58 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $74.28 | 2025 | Sotyktu |
| Pfizer INC. | $73.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.52 | 2021-2022 | |
| Abbott Laboratories | $68.47 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $50.36 | 2019-2020 | |
| Allergan, INC. | $36.94 | 2019 | |
| Glaxosmithkline, LLC. | $27.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.78 | 2021-2022 | |
| Grifols USA, LLC | $15.51 | 2025 | Xembify |
| Radius Health, INC. | $13.78 | 2019 | |
| Neurocrine Biosciences, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.